SynthesisInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2023
Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
Synthesis in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases.Journal of clinical immunology · 2026Pooled it
- Systemic multi-omics analysis reveals interferon response heterogeneity and links lipid metabolism to immune alterations in severe COVID-19.Genome medicine · 2026Article
- Exploration of immune phenotypes in self-sampling citizens.iScience · 2026Article
- The Role of Anti-Interferon-α Autoantibodies in Severe COVID-19: Implications for Vaccination Prioritization.Vaccines · 2025Article
- Type I Interferons in SARS-CoV-2 Cutaneous Infection: Is There a Role in Antiviral Defense?International journal of molecular sciences · 2025Article
- ICAM-1 autoantibodies detected in healthy individuals and cross-react with functional epitopes.ImmunoHorizons · 2025Article
- mRNA-LNP vaccine-induced CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.JCI insight · 2024Observational
- Plasmonic Fluorescence Sensors in Diagnosis of Infectious Diseases.Biosensors · 2024Review
- No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.NPJ vaccines · 2024Article
- [SARS-CoV-2 infection and autoimmunity].Zeitschrift fur Rheumatologie · 2024Review
- Chest Computed Tomography Characteristics of Critically Ill COVID-19 Patients with Auto-antibodies Against Type I Interferons.Journal of clinical immunology · 2023Observational
- Severe acute herpes virus type 2 primo-infection and its association with anti-type 1 interferon autoantibodies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Role of autoantibodies targeting interferon type 1 in COVID-19 severity: A systematic review and meta-analysis.Journal of translational autoimmunity · 2023Article
- Chest computed tomography characteristics of critically ill COVID-19 patients with auto-antibodies against type I interferons.Research square · 2023Article
- Autoantibodies to Interferons in Infectious Diseases.Viruses · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables.
methodsA systemic review with the search terms: "COVID-19" or "SARS-CoV-2" and "autoantibodies" or "autoantibody" and "IFN" or "interferon" for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated.
resultsWe identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%).
conclusionSevere COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.